Stephanie Green

Brief butyltin exposure induces irreversible inhibition of the cytotoxic function on human natural killer cells, in vitro.

Interleukins 2 and 12 produce recovery of cytotoxic function in tributyltin-exposed human natural killer cells.

Factorial design considerations.

Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.

Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.

Statistics in clinical trials.

Do estimates of long-term survival tell us whether patients diagnosed with breast cancer before age 50 years are ever cured?

Exploratory evidence on the market for effective depression care in Pittsburgh.

A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.

Tributyltin exposure causes decreased granzyme B and perforin levels in human natural killer cells.

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.

An ethnographic study of collaborative clinical trial protocol writing.

Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

An analysis of reporting of sexually transmissible infections in indigenous Australians in mainstream Australian newspapers.

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.

DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice.

Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice.

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

Semiquantitative assessment of focal cartilage damage at 3T MRI: a comparative study of dual echo at steady state (DESS) and intermediate-weighted (IW) fat suppressed fast spin echo sequences.

A card before you leave: participation and mental health in Northern Ireland.

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Toward enabling winter occupations: testing a winter coat designed for older adults.

Semiquantitative assessment of subchondral bone marrow edema-like lesions and subchondral cysts of the knee at 3T MRI: a comparison between intermediate-weighted fat-suppressed spin echo and Dual Echo Steady State sequences.

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus.

Risk factors for MRI-detected patello-femoral and tibio-femoral cartilage loss during a 6-month period: The JOG study.